



PCT

特許協力条約に基づいて公開された国際出願

| | | |
|---|--|---|
| <p>(51) 国際特許分類6 C07D 215/46, 217/14, 217/22, 237/28, 239/74, 239/86, 239/91, 401/06, 405/12, 405/14, 471/04, 487/04, 491/044, 491/052, 495/04, A61K 31/47, 31/495, 31/50, 31/505</p> | <p>A1</p> | <p>(11) 国際公開番号 WO97/47601</p> <p>(43) 国際公開日 1997年12月18日(18.12.97)</p> |
| <p>(21) 国際出願番号 PCT/JP97/01993</p> <p>(22) 国際出願日 1997年6月9日(09.06.97)</p> <p>(30) 優先権データ 特願平8/149620 1996年6月11日(11.06.96) JP</p> <p>(71) 出願人 (米国を除くすべての指定国について) 吉富製薬株式会社 (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.)[JP/JP] 〒560 大阪府豊中市夕日丘二丁目11番37号 Osaka, (JP)</p> <p>(72) 発明者 ; および</p> <p>(75) 発明者 / 出願人 (米国についてのみ) 黒板孝信(KUROITA, Takanobu)[JP/JP] 都甲圭史(TOGO, Yoshifumi)[JP/JP] 石渕正剛(ISHIBUCHI, Seigo)[JP/JP] 藤尾雅和(FUJIO, Masakazu)[JP/JP] 二村隆史(FUTAMURA, Takashi)[JP/JP] 〒871 福岡県築上郡吉富町大字小祝955番地 吉富製薬株式会社 創薬第二研究所内 Fukuoka, (JP)</p> | <p>(74) 代理人 弁理士 高島 一(TAKASHIMA, Hajime) 〒541 大阪府大阪市中央区平野町三丁目3番9号(湯木ビル) Osaka, (JP)</p> <p>(81) 指定国 AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO特許 (GH, KE, LS, MW, SD, SZ, UG), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), 欧州特許 (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI特許 (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>添付公開書類 国際調査報告書</p> | |
| <p>(54)Title: FUSED HETEROCYCLIC COMPOUNDS AND MEDICINAL USES THEREOF</p> <p>(54)発明の名称 縮合ヘテロ環化合物およびその医薬用途</p> <p>(57) Abstract Fused heterocyclic compounds represented by general formula (I), optical isomers or pharmaceutically acceptable salts thereof, medicinal compositions comprising these compounds and pharmaceutically acceptable additives, and drugs comprising these compounds. These compounds exert more potent blocking effects on D₄ receptors than on D₂ receptors. Moreover, they have high affinities for receptors other than dopamine receptors such as muscarine M₁, serotonin-2 (5-HT₂) and adrenalin α₁ and α₂ receptors. Thus, these compounds are efficacious against not only positive symptoms typified by hallucination and delusion characteristic of the acute stage of schizophrenia but also negative symptoms such as emotional torpidity, abulia and autism. In addition, they are useful as antipsychotic agents with relieved side effects such as extrapyramidal symptoms and abnormal internal secretion observed in association with the administration of the conventional antipsychotic agents having only D₂ receptor antagonism. The above compounds are usable as remedies for diseases such as schizophrenia.</p> <div data-bbox="747 1260 1429 1617"> <p style="text-align: right;">(I)</p> </div> | | |